New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
17:14 EDTAMGN, QGENAmgen announces FDA approval of Vectibix in combination with FOLFOX
Amgen (AMGN) announced that the FDA has approved Vectibix for use in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. With this approval, Vectibix becomes the first and only biologic to offer a significant survival benefit as a first-line treatment with FOLFOX, one of the most commonly used chemotherapy regimens in the first-line setting for patients with wild-type KRAS mCRC. In addition, this approval converts the accelerated monotherapy approval to a full approval for Vectibix. FDA also approved the therascreen KRAS RGQ PCR Kit developed by QIAGEN (QGEN) as a companion diagnostic for Vectibix.
News For AMGN;QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
08:04 EDTAMGNWest Pharmaceutical's Daikyo Crystal Zenith selected by Amgen
Subscribe for More Information
February 10, 2016
07:15 EDTAMGNLeerink to hold a conference
Subscribe for More Information
February 9, 2016
16:13 EDTQGENQIAGEN, 10x Genomics enter co-marketing, co-development collaboration
QIAGEN announced a collaboration with 10x Genomics to develop and promote comprehensive solutions for next-generation sequencing, or NGS, single-cell biology and bioinformatics. This collaboration includes: Optimizing QIAGEN's sample technologies for use with 10x Genomics GemCode and Chromium systems. This includes QIAGEN's MagAttract HMW DNA kit to deliver high-quality, high molecular weight, or HMW, DNA through a simple and fast workflow. The enhanced performance of integrating QIAGEN and 10x Genomics technologies will be shown at the Advances in Genome Biology and Technology, or AGBT, meeting in Orlando, FL, from February 10-13. Supporting complete workflows in single-cell biology by leveraging 10x Genomics' revolutionary GemCode technology with QIAGEN's leading single-cell biology portfolio and QIAseq NGS solutions. Investigating the implementation of 10x Genomics' GemCode technology with QIAGEN's proprietary GeneReader NGS System, the world's first complete NGS workflow designed for any lab. The combination will result in upgraded capabilities of QIAGEN's Sample to Insight solutions for NGS such as allowing customers to detect structural variants, haplotypes and other valuable long-range information from DNA inputs as little as 1ng. Enabling the processing and analysis of 10x Genomics' "Linked-Reads" with QIAGEN's suite of leading bioinformatics solutions. These efforts aim to address the challenges of data analysis, interpretation, clinical decision-support, and reporting that rely on testing for long-range phasing and structural variants in genomics. Co-marketing each other's applications, including QIAGEN's sample technologies, QIAseq NGS solutions, and QIAGEN Bioinformatics along with 10x GemCode Platform and Chromium products.
February 8, 2016
15:59 EDTAMGNU.K. cost regulator reverses stance on Amgen's Repatha, PharmaTimes says
The U.K.'s National Institute for Health and Care Excellence has reversed its prior decision barring patients from accessing Amgen's cholesterol treatment Repatha, reports PharmaTimes. The agency will now allow use of the drug, alone or in combination with other therapies, for various classes of patients, though only at a 140mg biweekly dose and only as long as the company continues to offer certain discounts, the report noted. Reference Link
February 5, 2016
09:26 EDTAMGNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:03 EDTAMGNAmgen resumed with a Market Perform at Leerink
Leerink analyst Geoffrey Porges resumed coverage of Amgen with a Market Perform rating and $179 price target.
February 4, 2016
19:15 EDTAMGNAmgen reinitiated with a Market Perform at Leerink
Target $179.
16:28 EDTAMGNAmgen reports BLINCYTO study met primary endpoint, stopped early for efficacy
Amgen announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study. The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO versus standard of care in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The independent data monitoring committee recommended, and Amgen has accepted, that the study end early for efficacy. The BLINCYTO adverse events observed in the TOWER study were consistent with the known safety profile of BLINCYTO. Secondary endpoints are currently being evaluated.
16:02 EDTAMGNAmgen says trial of Repatha meets co-primary endpoints
Subscribe for More Information
February 3, 2016
08:57 EDTAMGNPullback in biotech makes M&A more attractive, says UBS
UBS analyst Andrew Peters noted the pullback in small and mid-cap biotechs and said a consequence of the lower valuations may be an increased appetite for M&A by the larger firms. Peters noted Gilead (GILD) commented on its earnings call that "there's no question" the pullback has made M&A more attractive. UBS said with valuations so far off their highs, the question remains whether management and boards will accept deals at such depressed levels.
08:48 EDTAMGNWorkday appoints Diana McKenzie as Chief Information Officer
Subscribe for More Information
February 2, 2016
16:14 EDTQGENQIAGEN announces agreement with CosmosID Inc.
QIAGEN announced new partnerships to "enhance the profile and expand the use of its market leading bioinformatics solutions for microbiome, metagenomics and other applications." The company said, "QIAGEN Bioinformatics signed an agreement with genomics big data company CosmosID Inc., to allow users of QIAGEN's CLC Genomics Workbench to access and integrate CosmosID's metagenomics analysis platform into their QIAGEN bioinformatics platform. CosmosID's platform allows users to identify and characterize microbial communities from whole genome shotgun data and to determine their relative abundance. The new plug-in expands the range of metagenomic and microbiome applications supported by QIAGEN's microbial genomics solution enabling researchers in fields such as infectious disease, animal health, agriculture, environmental and food safety to use shotgun metagenomics analysis for routine testing employing next-generation sequencing."
16:12 EDTQGENQIAGEN says 'on course' to achieve the 2016 goals
Subscribe for More Information
16:12 EDTQGENQIAGEN reports Q4 adjusted EPS 31c, consensus 32c
Subscribe for More Information
08:53 EDTAMGNPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
February 1, 2016
08:25 EDTAMGNAlder pullback Friday a buying opportunity, says Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use